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Abstract
We have investigated the importance of interleukin-6 (IL-6) in promoting tumor growth and metastasis. In human
primary breast cancers, increased levels of IL-6 were found at the tumor leading edge and positively correlated with
advanced stage, suggesting a mechanistic link between tumor cell production of IL-6 and invasion. In support of this
hypothesis, we showed that the IL-6/Janus kinase (JAK)/signal transducer and activator of transcription 3 (Stat3)
pathway drives tumor progression through the stroma and metastatic niche. Overexpression of IL-6 in tumor cell
lines promoted myeloid cell recruitment, angiogenesis, and induced metastases. We demonstrated the therapeutic
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potential of interrupting this pathway with IL-6 receptor blockade or by inhibiting its downstream effectors JAK1/2 or
Stat3. These clinically relevant interventions did not inhibit tumor cell proliferation in vitro but had profound effects
in vivo on tumor progression, interfering broadly with tumor-supportive stromal functions, including angiogenesis,
fibroblast infiltration, and myeloid suppressor cell recruitment in both the tumor and pre-metastatic niche. This study
provides the first evidence for IL-6 expression at the leading edge of invasive human breast tumors and demonstrates
mechanistically that IL-6/JAK/Stat3 signaling plays a critical and pharmacologically targetable role in orchestrating the
composition of the tumor microenvironment that promotes growth, invasion, and metastasis.
Neoplasia (2013) 15, 848–862
Introduction
The aberrant tyrosine phosphorylation or activation of signal transducer
and activator of transcription 3 (pStat3) has been broadly characterized
as a regulator of tumorigenesis through its effects in both tumor cells
and the tumor microenvironment [1]. In contrast to normal cells in
which Stat phosphorylation is tightly regulated, Stat3 is persistently
phosphorylated in many cancers through increased production of posi-
tive effectors, such as specific cytokines and cytokine receptors, and
decreased expression of negative regulators, such as the SOCS proteins
and tyrosine phosphatases [2]. We and others have determined that
pStat3 is expressed in ∼40% of all breast cancers [3–6], particularly on
the leading edge of tumors in association with stromal cells [7]. pStat3
is expressed in the triple-negative (TN) subtype of breast cancer, in part
through autocrine expression of the inflammatory cytokine interleukin-6
(IL-6) [5,8–10]. Additionally, paracrine IL-6 can induce autocrine
IL-6 expression in adjacent cells, thus creating an IL-6+ niche [8]. The
IL-6 family of cytokines is produced by numerous cell types within a
tumor (e.g., cancer cells, bone marrow–derived cells, adipocytes, and
fibroblasts) and, coupled with the IL-6 receptor (IL-6R) and gp130
receptor, activates a Janus kinase (JAK)–dependent signaling cascade,
mediating tyrosine phosphorylation of Stat3.
The mechanisms by which this signaling pathway regulates mam-
mary tumorigenesis and metastatic progression are complex, involving
both tumor-intrinsic and tumor-extrinsic roles. For example, targeted
reduction of Stat3 in mammary epithelial cells has little effect on their
in vitro growth, while the in vivo consequences on tumor growth and
metastatic progression are significant and correlate with a reduction in
angiogenesis [11–14]. These observations suggest a context or micro-
environment-dependent role for the activation of the IL-6/JAK/Stat3
signaling pathway in regulating mammary tumorigenesis. The cells,
which constitute the tumor stroma (including endothelial cells, cancer-
associated fibroblasts, and bone marrow–derived cells), are recognized
as principal determinants of tumor progression [15–17]. Moreover,
many of these cells express pStat3 and targeting this transcription
factor in bone marrow–derived myeloid cells nearly abrogated the
growth of metastatic disease in models of melanoma and bladder can-
cer demonstrating the importance of myeloid-specific Stat3 activation
in metastatic progression [18–21]. Thus, IL-6/JAK/Stat3–driven reg-
ulatory programs in tumor cells are hypothesized to orchestrate the for-
mation of a pro-tumorigenic/metastatic microenvironment through
the activation of Stat3 in the stroma. However, the significance of
this signaling pathway in regulating the interactions among these
cell types as well as their function in mammary gland pathogenesis
remains unclear.
In this study, we demonstrated that high expression levels of IL-6 on
the leading edge of human mammary tumors positively correlated with
advanced stage, suggesting a role for this cytokine in promoting metasta-
sis. Increasing IL-6 levels in human breast cancer models induced metas-
tasis, which was associated with the mobilization of tumor-associated
suppressive myeloid cells and a robust stromal and endothelial cell infil-
trate. Additionally, pStat3, a principal target of IL-6 signaling, was co-
expressed with IL-6 in primary human specimens and in murine models
of breast cancer in both tumor cells and those comprising the micro-
environment including myeloid suppressor cells. Moreover, by knocking
out Stat3 in human and in transgenic mammary tumor cells, IL-6 levels
were significantly reduced, as were tumor growth and metastasis. A simi-
lar phenotype was observed by targeting IL-6 and JAKs using phar-
macological interventions. These data demonstrate the formation of an
autocrine/paracrine IL-6/JAK/Stat3 feed-forward loop, which partici-
pates in tumor proliferation, shaping of the tumor microenvironment,
and metastasis. The observed suppression of tumor growth and meta-
static potential through the use of clinically relevant inhibitors supports
the therapeutic potential of targeting this pathway in breast cancer.
Materials and Methods
Animal Studies
Female BALB/c, FVB, C57/BL6, IL-6−/− C57/BL6, athymic nude,
and non-obese diabetic/severe combined immunodeficiency mouse
(NOD/SCID) mice (5–8 weeks old) were obtained from NCI
(Frederick, MD) and Jackson Laboratory (Bar Harbor, ME). MMTV-
PyMT/MMTV-Cre/Stat3flox/flox mice were generated by crossing C57/
BL6 MMTV-PyMT transgenicmice (Ming Li,MSKCC)withC57/BL6
MMTV-Cre (Ming Li, MSKCC) and Stat3flox/flox mice (kindly pro-
vided by Hua Yu, City of Hope). Animal work was done in accordance
with a protocol approved by MSKCC’s Institutional Animal Care and
Use Committee (IACUC). For mammary fat pad (MFP) tumor injec-
tion, cells were harvested by trypsinization, washed twice in phosphate-
buffered saline (PBS), and resuspended in PBS (+30% Matrigel). The
fourth inguinal mammary glands of mice were revealed and 106 cells
were injected directly into the MFP. Microdissected (<1 mm) tumors
and/or equal numbers of mammospheres (103) were transplanted into
theMFP of 4- to 6-week-old female recipient mice. Mice bearing tumors
were treated with JAK inhibitor (JAKi), IL-6R blocking antibody
(IL-6RAb), or isotype control and vehicle (see Cell Lines, Antibodies,
and Drug Administration section). Tumor growth was monitored
weekly by measuring the tumor length (L) and width (W ), and volume
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was calculated as π × L ×W 2/6. For metastasis assays, MFP tumors were
surgically resected upon reaching a volume greater than 300 mm3,
and metastatic progression was assessed by bioluminescence imag-
ing (BLI; Xenogen IVIS System) and quantitative polymerase chain
reaction [PCR; green fluorescent protein positive (GFP+) tumor cells].
For lung colonization assays, 2 × 105 cells (0.1 ml) were injected into
the lateral tail vein. Photon flux (BLI) was measured and normalized to
the value obtained after xenografting at day 0.
Cell Lines, Antibodies, and Drug Administration
The tumor cell lines 4T1 and 67NR were provided by Dr Fred
Miller (Michigan Cancer Foundation) and the xenograft MARY-X
by Dr Mary L. Alpaugh (MSKCC). Met-1 cells were derived from
an MMTV-PyMT tumor (FVB background; provided by Dr Kent
Hunter, NCI). 4175 and 1833 cell lines were provided byDrMassague
(MSKCC) and express a reporter construct encoding GFP and firefly
luciferase for bioluminescent tracking [22]. The 1833–IL-6 over-
expression cell line was created by retrovirally introducing pBabe–IL-6
and pBabe control into the 1833 cell line selected with puromycin.
Individual clones were isolated and their relative IL-6 levels were de-
termined by ELISA. PyMT control and Stat3−/− PyMT cell lines were
generated from tumors derived from PyMT and Stat3−/− PyMT trans-
genic mice. Tumors were dissected and digested (collagenase III and
liberase; minimum essential medium (SMEM) medium, Invitrogen,
Carlsbad, CA; 37°C, 3 hours). Isolated cells were cultured in WIT
media (low attachment plates). Anti–IL-6R mAb (Tocilizumab) and
isotype control were provided by Dr Nori Nishimoto [23] and admin-
istered by intraperitoneal injection weekly. AZD1480 was provided by
AstraZeneca (Waltham, MA; Dennis Huszar). For in vitro studies,
AZD1480 was dissolved in DMSO; for in vivo studies, it was re-
suspended in 0.5% methylcellulose/0.1% Tween 80 and administered
by oral gavage twice daily.
Quantitative Reverse Transcription–PCR
Lung tissue from mice was homogenized and RNA extracted
in TRIzol reagent according to the manufacturer’s instructions
(Invitrogen) and reverse transcribed to cDNA using Superscript III
(Invitrogen). Gene expression was quantified by quantitative reverse
transcription–PCR [qRT-PCR; SyBR-Green PCR reactions; ABI
Prism 7900HT Sequence Detection System (Applied Biosystems,
Foster City, CA)]. GFP expression quantification was based on a stan-
dard curve (standardized dilutions of GFP; 3 × 102 to 3 × 106 copy
numbers), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
or β-actin was used as a housekeeping control transcript. The follow-
ing primer sequences were used: GFP-FW5′-CTGCTGCCCGAC-
AACCA-3′; GFP-RV5′-TCCAGCAGGACCATGTGATC-3′;
β-actin-FW5′-CGGTTGGCCTTAGGGTTCA-3′; β-actin-RV5′-
GTGGGCCGCTCTAGGCACCA-3′; GAPDH-FW5′-GAAAC-
CTGCCAAGTATGATGACAT-3′; GAPDH-RV5′-TTGTCATAC-
CAGGAAATGAGCTTG-3′; CSF1-FW5′-CAATGCTAACGCC-
ACCGAGAG-3′; CSF1-RV5′-CGGACACAGGCCTTGTTCTGC-
3′; ARG1-FW5′-GGAGACCACAGTCTGGCAGTTG-3′; ARG1-
RV5′-AGGACACAGGTTGCCCATGCAG-3′; IL-1β-FW5′-
CCAAAAGATGAAGGGCTGCTTC-3′; IL-1β-RV5′-AGCCA-
CAATGAGTGATACTGCC-3′; NOS2-FW5′-CTGCATCGGCAG-
GATCCAGTG-3′; NOS2-RV5′-TGATGGCCGACCTGATG-
TTGCC-3′; S100A8-FW5′-CAAGGAAATCACCATGCCCTC-
TAC-3′; S100A8-RV5′-CGATATTTATATTCTGCACAAACT-
GAGGAC-3′; S100A9-FW5′-CCTGACACCCTGAGCAAGAAG-3′;
S100A9-RV5′-CATTTCTCTTCTCTTTCTTCATAAAGG-3′. Dif-
ferences in the expression levels of genes were determined by calculating
the fold change in expression (2−ddCT).
Immunohistochemistry/Immunofluorescence
Tumors were fixed in 4% paraformaldehyde and embedded in paraf-
fin. Immunohistochemical and immunofluorescence (IF) experiments
were performed at the Molecular Cytology Core Facility (MSKCC)
using Discovery XT processor (Ventana Medical Systems, Oro Valley,
AZ). The primary antibodies used were pStat3 (Tyr705; 0.2 μg/ml; Cell
Signaling Technology, Boston MA), smooth muscle actin (SMA; 1 μg/
ml; Sigma, St Louis, MO), Meca-32 (3 μg/ml; DSHB, Iowa City, IA),
CD45 (0.25 μg/ml; BD, San Jose, CA), Gr1 and anti-mouse CD11b
(BD), and anti-human CD33 (Leica BOND). Corresponding bio-
tinylated secondary antibodies were purchased from Vector Laboratories
(Burlingame, CA). Tyramide–Alexa 488 and Alexa 568 (Invitrogen)
were used for double IF detection.
Immunohistochemical Analysis of IL-6 in Human Breast
Cancer Specimens
Forty-six surgical specimens, obtained from patients with ductal/
lobular breast carcinoma who underwent quadrantectomy or mastec-
tomy, were collected for immunohistochemical analysis (Table W1).
All the procedures were approved by Comitato Etico dell’Azienda
Ospedaliera, University of Bologna, and written informed consent
was obtained from patients (M.T.). Tissues were histologically clas-
sified according to World Health Organization (WHO) criteria and
graded following the classification described by Elston and Ellis. The
tumors were also typed by nuclear grading and classified as mild,
moderate, and severe nuclear atypia (graded 1, 2, and 3, respectively).
Tumor size and axillary lymph node involvement were also recorded
using pathological tumor-node-metastasis [pTNM; International Union
Against Cancer (UICC)] pathologic staging criteria. The cytoplasmic
IL-6–immunoreactive population was evaluated [anti–IL-6 antibody,
clone 1936; R&D Systems, Minneapolis, MN. Formalin fixed paraffin
embedded (FFPE) sections were subjected to antigen retrieval using a
Tris-EDTA buffer (pH 9.0) for 20 minutes and incubated with the
antibody (1:250) in PBS overnight at room temperature]. For each
field, the neoplastic cells were classified according to both positive per-
centage and staining intensity: percentage = 0 if <1%, 1 if >1% < 25%,
2 if >25% < 50%, 3 if >50% <75%, 4 if >75%; intensity = 1 (weak),
2 (moderate), and 3 (strong). A final classification was obtained by
multiplying the two mean values (percentage and intensity) and clas-
sifying the results (range, 0–12) as follows: score 0 (value = 0); score 1
(0.1–1); score 2 (>1 < 4); score 3 (>4 < 8); score 4 (>8). pStat3 levels
were determined as previously described [7].
Western Blot and ELISA
Whole-cell lysates were prepared as previously described [5], and
Western blot analysis was carried out by standard methods. Anti-
bodies used included Stat3, pStat3 (Cell Signaling Technology),
tubulin, and β-actin (Santa Cruz Biotechnology, Dallas, TX). IL-6
levels were examined from conditioned media (50–85% confluent
cells) or sera using an IL-6 ELISA Kit (R&D Systems) according
to the manufacturer’s instructions.
Flow Cytometry
Cells were isolated from tumor, spleen, or lung and stained with CD45
(Pe-Cy7 rat anti-mouse, 30-F11; BD), CD11b (APC rat anti-mouse,
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M1/70; BD), Gr1 (APC-Cy7 rat anti-mouse, RB6-8C5; BD), F4/80
(Brilliant Violet 421, anti-mouse, BM8; Biolegend, San Diego, CA),
CD3 (PE rat anti-mouse, 17A2; BD), and CD4 (PerCP rat anti-
mouse, RM4-5; BD). Cell viability was determined using LIVE/DEAD
Fixable Yellow Dead Cell Stain Kit (Invitrogen). Data were collected by
CyAn ADP Violet Cytometer (Dako Cytomation, Carpinteria, CA) and
analyzed with FlowJo (Tree Star, Ashland, OR). CD11b+/Gr1+ and
F4/80+ cells were isolated by fluorescence-activated cell sorter (FACS)
sorting (BD FACS Aria III).
Arginase and NO Assay
Splenic myeloid-derived suppressor cells (MDSCs) were isolated
using MACS cell isolation magnetic beads according to the manufac-
turer’s instructions (Miltenyi Biotech, Auburn, CA). The purity of the
resulting cells (>90% CD11b+/Gr1+) was assessed by flow cytometry.
Isolated MDSCs were activated by culturing 1 × 106 cells per 200-μl
well in Dulbecco’s modified Eagle’s medium containing 5% FBS plus
interferon gamma (IFN-γ; 2 ng/ml) and lipopolysaccharide (LPS;
100 ng/ml) in a 96-well plate for 24 hours. Arginase was quantified
by measuring the production of urea as described [24]. Absorbance
(urea concentration) was measured spectrophotometrically at 540 nm.
NO was measured using Griess Reagent System (Promega, Madison,
WI) according to the manufacturer’s instructions.
Statistical Analysis
Data are expressed as means ± SEM. The statistical significance of
differences was evaluated using an unpaired, nonparametric Student’s
t test. Significant differences between experimental groups were *P <
.05 or **P < .01.
Results
Consequences of IL-6 Expression on Mammary Tumorigenesis
IL-6 and pStat3 are co-expressed in a number of cancer subtypes,
including mammary tumors [5,7,10,25,26]. Paracrine IL-6 was shown
to promote autocrine expression of IL-6 within cancer cells [8,9],
suggesting a positive feed-forward loop, in which IL-6 engages with
IL-6R/gp130, resulting in JAK and Stat3 activation, which in turn
increases expression of autocrine IL-6 [27–29]. These observations
prompted us to examine the relative levels and distribution of IL-6
expression by immunohistochemistry in human primary breast cancers
Figure 1. Differential IL-6 expression in human breast cancer. (A) IL-6 expression was examined by IHC in 45 primary breast cancer
samples, 18 with matched axillary lymph nodes. Relative IL-6 levels [low (0, 1+) versus moderate/high (2, 3, 4+)] were determined and
found to be highest on the tumor edge, areas of LVI, and lymph nodes relative to the central portion of the tumor (P < .05, Fisher exact
C2). Normal lymph node inset displays no IL-6 expression. (B) IL-6 scoring. Cytoplasmic IL-6 immunoreactivity was evaluated at ×200
(see Materials and Methods section). Representative examples are shown. (C) Higher IL-6 levels on the tumor edge were associated with
number of lymph nodes involved with metastatic disease.
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including those with metastatic involvement in matched axillary lymph
nodes (Figure 1, A and B). We determined that the highest levels of
IL-6 were found on the tumor edge enriched in stromal/immune cells,
areas of lymphovascular invasion (LVI), and axillary lymph nodes. In
contrast, the central portion of the tumor expressed lower levels of
IL-6 (Figure 1A). Furthermore, Figure 1C depicts the positive cor-
relation observed between high IL-6 levels on the tumor edge and
the number of lymph nodes affected by metastatic disease (the most
important predictor of survival in breast cancer) [30]. These results
suggested to us that the relative levels and distribution of IL-6 in
breast tumors might play a role in metastatic progression. Additionally,
the lack of generalized IL-6 staining supports the idea of an inter-
dependence between tumor and stromal cells (frequently found on
the edge of tumors) as an important positive regulator of IL-6 expression
in cancers.
We hypothesized that autocrine/paracrine IL-6 expression from
tumor cells would lead to activation of Stat3 in both stromal and tumor
cells enhancing growth and metastasis. We therefore determined the
effects of modulating the levels of IL-6 and IL-6 signaling in human
breast cancer models on both primary tumor growth and metastasis.
We examined two TN breast cancer–derived cell lines with either
a high (4175) or no capacity (1833) to spontaneously metastasize
to the lung [22]. The 4175 cells expressed two-fold higher levels of
IL-6 and pStat3 compared to the 1833 cell line (Figure 2A). We
first determined if increasing the levels of IL-6 in the 1833 cells
(∼1800 pg/ml) to those observed in 4175 cells (∼2900 pg/ml) could
alter their growth in the lungs and MFP, as well as their capacity
to spontaneously metastasize to the lungs. We introduced an IL-6
retroviral expression vector in 1833 cells and selected several clones
that expressed two to four (∼4000 pg/ml) times more IL-6 than
vector-infected control cells (1833-pB), which correspondingly showed
relatively more pStat3 expression (Figure 2, A and B). We compared
the in vitro growth of 1833-pB and 1833–IL-6 cells and no differences
were observed, suggesting that IL-6 does not regulate proliferation
in a tumor-autonomous manner (Figure W1A). We compared the
in vivo growth of 1833-pB to 1833–IL-6 cells following tail vein (lung
colonization) and MFP injection by in vivo luciferase imaging. While
1833-pB cells never gave rise to lung metastases, 1833–IL-6 cells
grew in the lungs as effectively as 4175 cells (Figure 2C and data not
shown). Examination of the lungs of mice injected with 1833–IL-6
cells compared to those injected with 1833-pB cells revealed a 20-fold
increase in pStat3+ cells and a 5-fold increase in leukocytes (CD45+)
before the development of macro-metastatic disease (3 weeks after
injection; Figure 2D). The growth of 1833–IL-6 cells in the MFP
was significantly greater than that of the 1833-pB cells, demonstrating
a proliferative advantage (Figure 2E). A comparison of theMFP tumors
Figure 2. IL-6 expression promotes metastatic progression in the lung. (A) Conditioned media from 1833-pB (vector control), 4175, and
1833–IL-6 cells were analyzed for IL-6 levels by ELISA. (B) Extracts from 1833-pB, 4175, and 1833–IL-6 cells were analyzed for pStat3, Stat3,
and tubulin levels. (C) 1833-pB and 1833–IL-6 cells (1 × 105) were injected intravenously into mice, and tumor growth was determined
weekly by normalized BLI (n = 10 mice/group). Representative BLI images of mice from each group at week 7 are shown. (D) IHC staining
of CD45 and pStat3 expression in lung sections of 1833 vector control and 1833–IL-6–injected mice. Number of CD45+ and pStat3+ cells
are indicated/high-powered field (hpf; n = 10 images). (E) 1833 and 1833–IL-6 cells (1 × 106) were injected into the MFP of athymic nude
mice, and tumor growth was determined weekly by normalized BLI (n = 10 mice/group). (F) qRT-PCR for GFP (tumor cells: GFP+) was
performed on the RNA of lungs from 1833–IL-6 and 1833-pB primary tumor-bearing mice (n = 5/group; *P < .05).
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revealed higher levels/numbers of pStat3+ cells, leukocytes (CD45+),
myeloid cells (CD11b+/Gr1+), and endothelial cells (Meca-32) in the
1833–IL-6 compared to the 1833 tumors (Figure W1, B and C ). A
significant difference in the development of lung metastases was
observed between mice bearing 1833–IL-6 and 1833-pB MFP tumors
(as measured by qRT-PCR of GFP+ tumor cells). That is, 1833–IL-6
MFP tumors spontaneously metastasized to the lung, while 1833-pB
MFP tumors never gave rise to lung metastases regardless of primary
tumor size (Figure 2F ). These results demonstrated that a two- to
three-fold increase in tumor-derived IL-6 levels can dramatically
enhance inflammation in the tumor and pre-metastatic sites and alter
the fate of a cancer cell, rendering it capable of proliferating in distant
metastatic sites.
Conversely, we reasoned that blocking this cytokine and its associ-
ated signaling pathway would abrogate the metastatic process. Here,
we turned to IL-6RAb, which inhibited IL-6 signaling in 1833–IL-6
cells. Specifically, IL-6RAb was added to 1833–IL-6 cells leading to a
reduction in pStat3 levels (Figure W2A). We also demonstrated that
1833–IL-6 cells secrete both the soluble IL-6R (sIL-6R) and the IL-6
ligand, which form a complex with the gp130 receptor (both murine
and human). This signaling, known as trans-signaling, was effectively
blocked by the IL-6RAb (Figure W2B and data not shown). Notably,
the IL-6RAb had no effect on the in vitro growth of 1833–IL-6 cells
(data not shown).
To determine the effects of IL-6R blockade on tumorigenesis, we
colonized lungs and injected MFPs with 1833–IL-6 cells and mice
received either the IL-6RAb or isotype control antibody. The growth
of colonized cells in the lungs andMFP and the spontaneous metastases
were largely abrogated (Figure 3, A–D). The levels of pStat3+ cells,
endothelial cells (Meca-32+), leukocytes (CD45+), and CD11b+/Gr1+
cells were reduced in the MFP tumors and lungs of IL-6RAb–treated
mice (Figures W2, C–E , and 3, E and F ). These observations were
also determined in the 4175 cell line (expressing high levels of IL-6
and pStat3) in which IL-6RAb reduced MFP growth, spontaneous
metastases, and the growth of established lung metastases with an asso-
ciated decrease in pStat3+ leukocytes, endothelial cells, and CD11b+/
Gr1+ cells (data not shown). These findings demonstrate that two- to
three-fold fluctuations in IL-6 levels or IL-6 signaling blockade can
result in significant phenotypic consequences.
Stat3–IL-6 Feed-Forward Loop Regulates
Mammary Tumorigenesis
A principal target of IL-6 signaling is the Stat3 transcription factor.
Here, we observed, as with IL-6, that phosphorylated pStat3 was
expressed primarily on the edge of the tumors and in areas of LVI in
association with stromal cells (Figure 4A). These observations suggested
that Stat3 may positively regulate the expression of IL-6. Moreover,
chromatin immunoprecipitation (ChIP) results demonstrated Stat3
binding to the IL-6 promoter in 4175 breast cancer cells (Figure W3A)
[31,32]. These data led us to hypothesize that a positive feed-forward
loop may take place between Stat3 transcriptionally regulating IL-6
expression. We investigated whether the selective absence of Stat3
in mammary tumor cells would decrease IL-6 expression/paracrine
signaling, which we hypothesize would alter the tumor microenviron-
ment, consequently decreasing tumor growth and metastatic progres-
sion. Reduction of Stat3 levels by short hairpin-silencing RNAs to
Stat3 (Stat3-shRNA) in 4175 cells had no effects on in vitro growth
but potently reduced in vivo growth, which correlated with reduced
IL-6, CD45, and Meca-32 levels (Figure W3, B–E and data not
shown). Furthermore, 4175 cells silenced for Stat3 display an eight-fold
change in IL-6 mRNA (data not shown).
We next investigated the role of Stat3 in the transgenic MMTV-
PyMT model of mammary tumorigenesis, which recapitulates many
aspects of human breast cancer, from preinvasive lesions to invasive
carcinoma and metastatic disease [33]. High levels of nuclear pStat3
were observed on the invasive edge of tumors in association with
stromal cells. Conversely, well-differentiated areas of tumor with
few stromal cells expressed much lower levels of pStat3 (Figure 4A).
Conditional Stat3 (Stat3Flox/Flox) mice were bred with MMTV-
PyMT and MMTV-Cre mice, and the onset of mammary tumor
formation between the Stat3+ versus Stat3− MMTV-PYMT mice
was quite variable (6–8 months) [34]. Due to insufficient numbers
(attributable to poor breeding of the C57/BL6 strain), we were un-
able to determine the phenotypic consequences of Stat3 deficiency
on tumor initiation. Additionally, the MMTV-PyMT mice develop
innumerable tumor foci in their mammary glands, making it difficult
to monitor tumor growth and metastasis progression [33,35]. To
examine the growth and progression of single tumor foci over time,
we isolated multiple pairs of tumors from littermates (Stat3−/− vs
Stat3+/+ PyMT mice), generated cell lines from these tumors, and
confirmed that they either expressed or lacked pStat3/Stat3
(Figure W4A). Interestingly, the Stat3+/+ tumors had a robust stro-
mal cell infiltrate compared to Stat3−/− tumors upon initial culturing
(data not shown). We observed no differences in their in vitro growth
rates, relative numbers of stem-like cells (CD49f/CD24-positive
cells), or capacity to form mammospheres (which are enriched in
tumor-initiating cells [36]; Figure W4B and data not shown). In vivo
growth was assessed by orthotopically transplanting equal numbers of
mammospheres or small chunks (1 mm) of tumor (from littermates,
as described above) in the MFP of syngeneic (C57/BL6) hosts. Tumor
growth was significantly reduced in the Stat3−/− PyMT tumors
compared to control (Stat3+/+; Figure 4B). There was no evidence of
macroscopic metastases in the mice bearing Stat3−/− tumors, while
Stat3+/+ tumor–bearingmicehadwidelymetastatic disease (FigureW4C
and data not shown). Morphologically, the Stat3+/+ tumors were poorly
differentiated, displayed greater pleiomorphic features, and increased
vascular invasion compared to the Stat3−/− tumors (Figure 4C). Further
examination of these tumors revealed a reduction in pStat3 in both
tumor and stromal cells, blood vessel number (Meca-32), mesenchymal
cell infiltrate (SMA), and MDSCs (CD11b+/Gr1+) compared to the
Stat3+/+ tumors by immunohistochemistry (IHC) and FACS analyses
(Figure 4, C and D). We also observed an increase in the levels of
CD8+ T cells in the Stat3−/− compared to the Stat3+/+ tumors
(Figure W4D). Furthermore, the observed reduction in the number
of CD11b+/Gr1+ cells was also accompanied by their decreased expres-
sion of immunosuppressive cytokines, such as Arg1, Csf1, Il-1β, Nos,
S100a8, and S100a9 (Figure 4E).
Given this evidence, we hypothesized that many of the pStat3+ cells
in the tumor microenvironment of breast cancer patients would in-
clude immature myeloid cells, including MDSCs. We therefore per-
formed co-IF staining for pStat3 and CD33 (a pan-myeloid marker
that recognizes MDSCs [37,38]) in 20 primary invasive ductal carci-
nomas and determined that ∼30% of CD33+ cells were also pStat3+.
Moreover, these cells were found primarily within the tumor stroma
(Figure 4F). Thus, tumor-derived Stat3 appears to favor the presence
of an immune and mesenchymal cell infiltrate that constitutes a tumor-
promoting microenvironment.
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Additionally, analysis of the lungs of PyMT mice bearing Stat3+/+
versus Stat3−/− tumors (3 weeks after orthotopic injection) revealed
a significant reduction in the levels of pStat3+ cells and CD11b+/
Gr1+ cells (in the absence of lung metastases by morphologic analysis),
suggesting that Stat3-dependent tumor-derived factors mediate
the formation of a pro-inflammatory microenvironment or pre-
metastatic niche (i.e., the receptive environment within distant tar-
get organs that forms before metastasis of tumor cells; Figure 5A)
[39,40].
We hypothesized that IL-6 levels (a regulator of MDSC expansion)
would be reduced in Stat3−/− versus Stat3+/+ PyMT tumors [41,42]. In-
deed, IL-6 mRNA/protein levels were low in Stat3−/− versus Stat3+/+
tumor–derived cell lines, demonstrating a dependence for Stat3 on
autocrine IL-6 expression on Stat3 (data not shown). Moreover, the
lack of IL-6 in orthotopically transplanted tumor cells resulted in an
overall reduction in IL-6 mRNA levels in the tumor (both tumor
stroma and tumor cells) and a reduction in circulating IL-6 levels in
Stat3−/− versus Stat3+/+ tumor–bearing mice (Figure 5B). A requirement
Figure 3. IL-6R blockade inhibits growth of tumors and metastases and prevents metastatic progression. (A) 1833–IL-6 cells (1 × 105)
were injected into the tail vein (n = 10/group) and were randomized to receive weekly intraperitoneal injections of control IgG (C) or
IL-6RAb (IL-6R) given at the time of injection. Tumor growth was determined weekly by normalized BLI. Representative lung images are
shown. (B) qRT-PCR for GFP relative to β-actin (tumor cells: GFP+) was performed to quantify tumor lung colonization described in A (n= 5).
(C) 1833–IL-6 cells (1 × 106) were injected into theMFP of athymic nudemice and randomized to receive weekly intraperitoneal injections of
control IgG (C) or IL-6RAb (IL-6R). Growth was determined weekly by normalized BLI. (D) qRT-PCR for GFP was performed on the lungs of
mice (n=5) in C. Quantification of CD11b+ and Gr1+ cells/hpf in the lungs (E) andMFP tumors (F) of mice described in A and C, respectively
(n = 10 sections/group; **P < .01, *P < .05).
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Figure 4. Stat3 deficiency abrogates tumorigenesis. (A) Representative IHC images examining pStat3 expression within the central portion,
edge, and invasive (lymphovascular invasion) regions of human and MMTV-PyMT breast cancers. (B) Tumor pieces (1 mm) from Stat3+/+
(PyMT S3+) and Stat3−/− (PyMT S3−) PyMT-bearing mice were implanted orthotopically in the MFP of syngeneic C57/BL6 hosts, and
tumor growth (volume and weight) was determined over 3 weeks (n = 8/group). (C) Representative histologic images of PyMT S3+ and
PyMT S3− tumors stained for hematoxylin and eosin (H&E), pStat3, SMA, andMeca-32. (D) Flow cytometric analysis of PyMT S3+ and PyMT
S3− tumors for CD11b+/Gr1+ cells (n = 5/group). (E) qRT-PCR analysis to determine the fold change (2−ddCT) in the expression of Stat3-
regulated genes in CD11b+/Gr1+ cells isolated from PyMT S3+ and PyMT S3− tumors. (F) Representative co-IF staining for pStat3 and CD33
in primary invasive ductal carcinomas (n = 20). Thirty-three percent of the CD33+ cells were also pStat3+ (**P < .01).
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for stromal IL-6 in tumorigenesis was determined by implanting
Stat3+/+ PyMT tumors in IL-6–deficient and wild-type (WT) mice.
The lack of host-derived IL-6 suppressed tumor growth even further
(Figure 5C). Overall, these data suggest the presence of an IL-6/Stat3
autocrine/paracrine feed-forward loop with profound effects on tumor
size and metastatic potential primarily due to alterations in the tumor
and pre-metastatic microenvironment.
Effects of JAK Inhibition on the Tumor Microenvironment
JAKs are the mediators of IL-6 signaling that phosphorylate/
activate Stat3. Inhibitors of JAKs have been shown to not only reduce
Stat3 phosphorylation (pStat3) but also reduce cytokine levels (includ-
ing IL-6) in patients with myeloproliferative disorders (MPDs) [43]. In
this study, we examined the effect of JAK1/2 inhibition on tumor
growth and spontaneous metastatic progression in a number of breast
cancer models with differential expression levels and distribution of
pStat3.We first examined the effects of JAK inhibition in the transgenic
MMTV-PyMT model. Treatment of mice bearing multiple sponta-
neous mammary tumors with JAKi led to a significant reduction in
tumor growth and abrogated the appearance of new tumors and the for-
mation of metastasis, compared to vehicle-treated mice (Figure 6A and
data not shown). Immunohistochemical staining of the tumor demon-
strated a reduction in pStat3 levels in both the tumor and its stroma
and a reduction in infiltrating endothelial (Meca-32) and fibroblast/
myoepithelial cells (SMA+; Figure 6B).
In addition to this transgenic model of mammary tumorigenesis, we
also examined the role of JAK inhibition in orthotopic mammary
tumor models, including the murine PyMT-derived cell line Met-1,
the human inflammatory breast cancer xenograft MARY-X, and the
4T1 murine mammary tumor model [44–46]. JAKi treatment of
Met-1 cells in vitro (1 μM) suppressed Stat3 phosphorylation status;
however, it had no effect on the in vitro proliferation of the cells
(Figure 6C ) as also reported for other cell lines (14). Similarly to
MMTV-PyMT, administration of JAKi significantly reduced tumor
growth, which correlated with a reduction in pStat3, Meca-32, and
SMA expression (Figure 6, D and E ). The MARY-X model of in-
flammatory breast cancer expresses very low levels of pStat3 in tumor
cells but high pStat3 in the surrounding stroma. Treatment of these
xenografts with JAKi led to a reduction in tumor size in conjunction
with a decrease in pStat3 expression, angiogenesis (Meca-32), and
SMA levels in the stroma (Figure 6, F and G ). Additionally, we
examined the 4T1 murine model of mammary tumorigenesis. As with
the other cell lines, JAKi reduced pStat3 levels and had no effect on
in vitro growth (Figure 7A), but a significant reduction in lung colo-
nization, tumor growth, and spontaneous lung metastasis follow-
ing JAKi administration was observed (Figure 7, B and C ). IHC
staining of 4T1 tumors of mice treated with JAKi revealed a marked
reduction in pStat3 levels in both the tumor and stromal cells as well
as in Meca-32 and SMA levels, compared to vehicle-treated mice
(Figure 7D).
Given our observation that a reduction in IL-6/Stat3 signaling
correlated with decreased MDSCs (see Figure 4D), we examined the
effect of JAKi on the immune cell infiltrate in tumor-bearing mice.
Flow cytometric analysis of the 4T1 MFP tumors revealed an increase
in CD3+, CD4+, and CD8+ cells (Figure 8A) and a reduction in the
levels of CD11b+/Gr1+ cells in MMTV-PyMT, Met-1, and 4T1
MFP tumors and in pre-metastatic sites as a consequence of JAKi treat-
ment (Figure 8B). Moreover, CD11b+/Gr1+ cells isolated from 4T1
tumors had reduced expression levels of immunosuppressive factors,
such as Arg1, Csf1, Il-1β, Nos, S100a8, and S100a9 compared to their
control counterparts, as determined by qRT-PCR (Figure 8C ). A
functional analysis of the isolated CD11b+/Gr1+ cells revealed a re-
duction in arginase (urea) and nitric oxide production, suggesting
that the CD11b+/Gr1+ cells (MDSCs) isolated from JAKi-treated
tumor-bearing mice are hypofunctional (Figure 8D). In addition to
CD11b+/Gr1+ cells, we also observed a trend to a decrease in the num-
ber of the pro-inflammatory tumor-promoting CD11b+/F480+ cells in
the tumors of JAKi-treated mice (Figure 8E ). However, qRT-PCR
analysis of F4/80+ cells isolated from 4T1 tumor–bearing mice re-
vealed a reduction in the expression levels of the tumor-promoting M2
growth factors, including Arg1, Il-10, Fizz1, Ccl2, and Ym1 following
JAKi administration (Figure 8F). These data suggest that JAK inhibi-
tion promotes an antitumor response in part through the reduction of
tumor-promoting immune cells (CD11b+/Gr1+, F4/80+).
Discussion
IL-6 is a pro-inflammatory cytokine produced primarily by the cells
comprising the tumor microenvironment (e.g., fibroblasts, myeloid
cells, and lymphoid cells) and has been characterized as a potent acti-
vator of Stat3. In this study, we demonstrate that the presence of high
IL-6 expression on the invasive edge of breast cancers in association
with stromal cells correlates with the degree of involvement of lymph
nodes in cancer, a marker of poor prognosis [30]; in contrast, IL-6 levels
Figure 5. Tumor-extrinsic effects of Stat3 deficiency. (A) Representative IHC images of the lungs of tumor-bearing (PyMT S3+ and PyMT S3−)
mice stained for pStat3. The proportion (%) of CD11b+/Gr1+ cells in the lungs of thesemicewas determined by flow cytometry. (B) IL-6 levels
in the serum were determined by ELISA and tumors were determined by qRT-PCR in PyMT S3+ and PyMT S3− mice, respectively
(n=5/group). (C) Tumor pieces (1mm) frommice bearingStat3+/+ (PyMTS3+) cancerswere implanted orthotopically in theMFPof syngeneic
(C57/BL6) IL6+/+ and IL-6−/− hosts, and tumor growth (weight) was determined after 3 weeks (n = 4/group). **P < .01, *P < .05.
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are comparatively lower in areas devoid of stroma such as the central
portion of tumors. These data suggest a role for IL-6 in promoting
invasion and metastasis. Additionally, we observed that the hetero-
geneity in IL-6 expression is mirrored by the heterogeneity in pStat3
expression. The heterogeneity or localized distribution of IL-6/pStat3
staining suggests multiple hypotheses. For example, paracrine sources
of IL-6 from tumor cells lead to the activation of pStat3 and IL-6
expression in cancer-associated fibroblasts, endothelial cells, and
myeloid cells, which in turn enhances a paracrine/autocrine IL-6/
JAK/Stat3 signaling loop within the stroma-rich areas of a tumor
Figure 6. JAK inhibition abrogates in vivo but not in vitro growth of transgenic and orthotopic mammary tumors. (A) MMTV-PyMT tumor–
bearing transgenic mice (n = 8) were treated with vehicle (C) or JAKi (AZD1480, 30 mg/kg twice daily). The size of tumors was determined
weekly. JAKi-treatedmice, compared to control mice, did not develop any newmammary tumors. (B) Representative IHC images of tumors
from vehicle- (C) and JAKi-treated MMTV-PyMT tumor–bearing mice stained for pStat3, Meca-32, and SMA. (C) Met-1 mammary breast
cancer cells were grown in culture and treated with JAKi (1 μM) or vehicle control (C). Extracts from these cells were analyzed for pStat3
and Stat3 by Western blot. (D) Met-1 cells (1 × 105) were injected into the MFPs of FVB mice, and when tumors reached ∼400 mm3,
mice were treated with JAKi (30 mg/kg twice daily) or vehicle control (C). Tumor size was determined after 3 weeks (n = 5/group). (E) Rep-
resentative IHC images of Met-1 tumors from control (C) and JAKi-treated mice for pStat3, Meca-32, and SMA. (F) MARY-X cells were
orthotopically injected into the MFPs of nude mice, and when tumors reached 150 mm3, mice were treated with either vehicle control
(C) or JAKi (30 mg/kg twice daily). (G) Representative IHC staining patterns for pStat3, Meca-32, and SMA of MFP tumor sections from
control (C) or JAKi-treated mice.
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[8,9,13]. It would also suggest an interdependence between tumor and
stromal cells to positively regulate IL-6 expression in cancers. Addition-
ally, differential expression of the negative regulators of IL-6 and pStat3
expression (e.g., the nuclear hormone receptors, suppressors of cyto-
kine signaling, protein inhibitors of activated Stat3, and tyrosine phos-
phatases) and the positive regulators of IL-6 [nuclear factor-kappa β
(NF-κβ) and CCAAT/enhancer-binding protein β (CEBPβ)] may
account for the localized distribution of IL-6/pStat3.
The presence of this regulatory loop is supported by our data dem-
onstrating that genetic disruption of Stat3 in tumor cells led to a
reduction in IL-6 expression in the tumor and in the circulation of
tumor-bearing mice. As a consequence, pStat3 expression was re-
duced in tumor-extrinsic stromal cells and in pre-metastatic sites, such
as the lungs. Additionally, pharmacological blockade of tumor-derived
IL-6/IL-6R signaling led to a reduction in pStat3 in the tumor, in-
cluding the stroma and pre-metastatic and metastatic sites of disease.
Conversely, increasing tumor IL-6 levels led to an increase in pStat3 in
tumor and associated stromal cells. Thus, by interfering with IL-6,
JAK, or Stat3, we can disrupt the pro-tumorigenic cross talk between
tumor and stromal cells.
Interestingly, the in vitro versus in vivo phenotypic consequences
of both enhancing or disrupting the IL-6/JAK/Stat3 pathway support
the hypothesis that the principal function of this pathway in regulat-
ing mammary tumorigenesis is through its effects on the tumor, pre-
metastatic, and metastatic microenvironments. Specifically, increasing
IL-6 levels or blocking its activity (IL-6R blocking antibodies, JAK
inhibition, or reducing Stat3 levels) had no effects on in vitro growth.
In contrast, overexpression of tumor-derived IL-6 induced metastasis
and tumor growth, while interfering with this signaling pathway sup-
pressed growth and metastatic progression. These observations are
Figure 7. JAK inhibition has no in vitro growth effects yet inhibits tumor growth and metastasis of 4T1 mammary cancers. (A) 4T1 breast
cancer cells were grown in culture treated with JAKi (1 μM) or vehicle control. Calcein AMwas performed daily (C). Extracts from these cells
were analyzed for pStat3 and Stat3 by Western blot. (B) 4T1 cells were injected into the tail vein of mice (1 × 105), and once BLI values
reached ∼5 × 106, mice were randomized to receive vehicle control (C) or JAKi (30 mg/kg twice daily). Normalized BLI signal of the mice
(n = 10/group) was determined weekly. (C) 4T1 cells (2 × 105) were injected into the MFP of BALB/c mice, which were randomized to
receive vehicle (C) or JAKi (30 mg/kg twice daily). Normalized BLI signals of MFP (n = 10/group) were determined weekly. Tumor weight
and spontaneous lung metastasis for either vehicle (C) or JAKi-treated mice were determined after 3 weeks. (D) Representative IHC images
of tumors from vehicle (C) and JAKi-treated 4T1 tumor–bearing mice stained for pStat3, CD45, Meca-32, and SMA. **P < .01, *P < .05.
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consistent with studies conducted by a number of investigators, which
show that the in vitro growth effects of inhibiting JAK/Stat3 signaling
are nominal compared to the striking in vivo effects in models of mam-
mary tumorigenesis [11,13,14,47]. Although blockade of the IL-6/
JAK/Stat3 pathway prevented tumor growth, there was no evidence
of tumor regression, which is consistent with the absence of any direct
cytotoxic tumor cell–intrinsic effects upon inhibition of this pathway.
While it was suggested that the IL-6/JAK/Stat3 pathway plays a role in
the development of tumor-initiating cells [10,48], we saw no evidence
to support this in the murine MMTV-PyMT model of mammary
tumorigenesis. For example, the absence of Stat3 had no effect on
mammosphere formation/growth or on the relative numbers of
tumor-initiating cells.
The significance of JAK signaling on the tumor microenvironment
is supported by our data demonstrating the growth-suppressive effects
of JAK inhibition on a pStat3−/− tumor surrounded by pStat3+/+
stromal cells. Additionally, the effects of IL-6/JAK blockade were more
pronounced on metastasis than on primary tumor growth, which we
Figure 8. JAK inhibition alters the cellular immune phenotype of the tumor microenvironment. (A) The proportion (%) of CD3+, CD4+,
and CD8+/CD45+ cells (n = 5/group) found in the tumors of 4T1 tumor–bearing mice treated with vehicle control (C) or JAKi (30 mg/kg
twice daily) was determined by flow cytometry. (B) Flow cytometric analysis for CD11b+/Gr1+ cells in tumors and lungs of mice bearing
MMTV-PyMT, Met-1, and 4T1 MFP tumors treated with vehicle control or JAKi (30 mg/kg twice daily). (C) qRT-PCR analysis to determine
the fold change (2−ddCT) in the expression of Stat3-regulated genes in CD11b+/Gr1+ cells isolated from 4T1 tumors treated with vehicle
(C) or JAKi (30 mg/kg twice daily). (D) The urea and NO2
− concentrations observed in the CD11b+/Gr1+ cells isolated from 4T1 tumor–
bearing mice treated with vehicle control (C) or JAKi (30 mg/kg) were determined by arginase and NO assays, respectively (n = 6/group).
(E) The proportion (%) of CD11b+ and F480+ cells (n = 5/group) found in the tumors of MMTV-PyMT transgenic mice and in Met-1 and
4T1 xenografts from mice treated with vehicle control (C) or JAKi (30 mg/kg) was determined by flow cytometry. (F) qRT-PCR analysis to
determine the fold change (2−ddCT) in the expression of immunosuppressive genes (Arg1, Il-10, Ccl2, Fizz1, Ym1, Ifnγ, S100a8, and
S100a9) from CD11b+/F480+ cells isolated from 4T1 xenografts from tumor-bearing mice treated with vehicle control or JAKi (30 mg/kg
twice daily; **P < .01, *P < .05).
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hypothesize is due to the significant contribution of a pStat3+ micro-
environment to metastatic progression. For example, reducing Stat3 in
myeloid cells alone led to a potent reduction in metastatic growth of
melanoma and bladder cancer [18,40]. These observations further
support the prominent role of the IL-6 signaling pathway on tumor
stroma, including endothelial cells, fibroblasts, and cells of the immune
system, which are active participants in vasculogenesis/angiogenesis,
inflammatory and immune-suppressive responses, and initiating and
promoting tumor progression and metastasis.
The phenotypic consequences of modulating the IL-6/JAK/Stat3
pathway described above correlated with changes in the abundance
of cancer-associated fibroblasts, endothelial cells, lymphocytes, and
myeloid cells, as well as with changes in their activity. In this study,
we observed that both IL-6 and pStat3 levels were highest on the in-
vasive edge of the mammary tumors, which coincided with an abun-
dance of fibroblasts, endothelial cells, and MDSCs (CD33+ in human
specimens and CD11b+/Gr1+ cells in murine models). Overexpression
of IL-6 in human orthotopic xenograft models increased the levels
of these stromal cells, including endothelial (Meca-32+), fibroblast
(SMA+), and myeloid cells (CD11b+ and Gr1+) within the tumor
and in the pre-metastatic niche, which were essentially reversed upon
treatment with IL-6RAb. Additionally, Stat3−/− tumors compared to
Stat3+/+ tumors had few endothelial, fibroblast, and myeloid cells.
Finally, treatment of tumor-bearing mice with JAKi led to a decrease
in the number of MDSCs recruited to the tumor stroma and to the
pre-metastatic sites. The link between MDSCs and Stat3 expression
in the promotion of metastasis is well established, since the accumula-
tion of MDSCs plays a key role in the formation of the pre-metastatic
niche [18,40].
Moreover, the presence of MDSCs within the tumor and metastatic
stroma favors the creation of an immunosuppressive environment by
triggering T cell anergy, inhibiting host-mediated antitumor responses
[49,50]. For example, Stat3 inactivation in myeloid or T cells aug-
mented the effector functions of adoptively transferred T cells induc-
ing tumor regression [18,19]. In this study, we show that targeting
the IL-6/JAK/Stat3 pathway resulted in reduced expression levels of
Figure 9. The IL-6/JAK/Stat3 feed-forward loop drives mammary tumorigenesis. A schematic diagram demonstrating that the selective
targeting of the IL-6/JAK/Stat3 signaling pathway (IL-6mAb, JAKi, Stat3−/−) has tumor-extrinsic effects on angiogenesis (Meca-32+), fibro-
blasts (SMA+), and the immune microenvironment [specifically, a decrease in the levels of pro-inflammatory CD11b+/F480+ and CD11b+/
Gr1+ cells and an increase in T (CD4+, CD8+) cell responses]. These effects are IL-6–dependent and result in a decrease in tumor size
and metastatic potential.
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Stat3-regulated genes, such as S100a8, S100a9, and IL-1β, in MDSCs
isolated from S3−/− or JAKi-treated tumor-bearing mice. Additionally,
a concomitant increase in T cell numbers (CD3+, CD4+, CD8+) was
observed, suggesting the possible initiation of an antitumor response.
This is further supported by a decrease in the proportion of the pro-
inflammatory tumor-promoting macrophages (CD11b+, F4/80+) upon
JAKi administration and a reduction in the expression levels of the
immunosuppressive M2 markers Il-10, Ccl2, Arg1, Fizz1, and Ym1.
Our results reveal the presence of a feed-forward loop elicited by
the tumor that involves IL-6 expression, which correlated with poor
prognosis, and subsequent phosphorylation of Stat3 in cells that con-
stitute the tumor, pre-metastatic, and metastatic microenvironments
(Figure 9). This IL-6/Stat3–regulated interplay within the tumor
stroma determines tumor proliferation, angiogenesis, inflammatory
status, and metastatic potential. For example, the observed low levels
and hypofunctional properties of MDSCs in association with reduced
tumor burden (including immunocompromised xenografts) have a
direct effect on angiogenesis as well as on the activity of other
tumor-associated cells [20]. However, the lack of regression with
IL-6R blockade or JAKi treatment encourages the identification of
combination approaches that can enhance an antitumor response, such
as the addition of agents that enhance T cell responses such as anti-
bodies blocking programmed cell death-1 or cytotoxic T-lymphocyte
antigen 4 and those that target cells for antibody-dependent cellular
cytotoxicity or in conjunction with cytotoxic agents [51]. Agents that
target tumor stroma, especially macrophages and myeloid cells, are
presently being investigated in clinical trials based on encouraging
preclinical studies in breast cancer models [52]. We suggest that anti–
IL-6/JAK/Stat3 therapies will function as potent antineoplastic agents
in those malignancies or conditions, in which the stroma plays a sig-
nificant role in regulating tumor growth and metastasis.
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Supplemental Materials and Methods
4175 cell line was provided by Dr Massague (MSKCC) and express
a reporter construct encoding GFP and firefly luciferase for bio-
luminescent tracking [1].
Stat3-shRNA lentiviral and scrambled control shRNA constructs
were previously described [2]. Murine Stat3 retroviral construct was
introduced into the 4175ShS3 cells to assess for off-target effects of
the Stat3-ShRNA.
4175 cells were cross-linked with 1% formaldehyde before being
harvested and sonicated. ChIP was performed as previously described
[3]. PCR was done with IL-6 promoter primers (sense, 5′-AAACT-
TCGTGCATGACTTCAGC-3′; antisense, 5′-CCAGTCCTATA-
TTTATTGGGGG′). The supernatant before IP was used as an
input control.
Tumors were fixed in 4% paraformaldehyde and embedded in
paraffin. Tissue sections were stained for IL-6 using anti–IL-6
(1:200; Abcam, Cambridge, MA) using previously described methods
[2]. Imaging was carried out on a Leica Inverted Confocal Microscope.
All other methods are described in the manuscript.
PyMT control and Stat3−/− PyMT cell lines were generated from
tumors derived from PyMT and Stat3−/− PyMT transgenic mice.
Tumors were dissected and digested (collagenase III and liberase;
SMEM medium; Invitrogen; 37°C, 3 hours). Isolated cells were
cultured in WIT media (low attachment plates).
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[2] Leslie K, Gao SP, Berishaj M, Podsypanina K, Ho H, Ivashkiv L, and Bromberg
J (2010). Differential interleukin-6/Stat3 signaling as a function of cellular
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H, Gerald W, Hassimi M, et al. (2011). Stat3 mediates expression of autotaxin
in breast cancer. PLoS One 6, e27851.
Table W1. Immunopathologic Table of Forty-Six Breast Cancer Tissues (IDC, Infiltrating Ductal Carcinoma; ILC, Infiltrating Lobular Carcinoma) from Primary Tumors, Matched Lymphovascular
Tumor Emboli (LVI), and Axillary Lymph Node Metastases.
Age Histotype LVI Diameter (mm) pT pN pNcod No. LN Pos G NG IL-6 Mas IL-6 Fr IL-6 LVI IL-6 LN
46 IDC No 20 T1 N1 Pos 1 G2 NG2 1 1 1
72 IDC No 18 T1 N2 Pos 5 G2 NG3 0 2 2
73 IDC Yes 25 T2 N3 Pos 10 G2 NG2 2 3 4 3
58 IDC Yes 15 T1 N2 Pos 7 G3 NG3 2 3 4 4
85 ILC No 15 T1 N1 Pos 2 G1 NG2 2 2 1
62 IDC No 17 T1 N3 Pos 16 G3 NG3 2 3 3
71 IDC Yes 20 T1 N1 Pos 1 G2 NG2 0 0 0
92 IDC No 14 T1 N0 Neg 0 G1 NG2 1 1
58 IDC No 20 T1 N0 Neg 0 G3 NG3 1 1
83 IDC No 18 T4 G1 NG2 0 1
83 IDC No 12 T1 N3 Pos 16 G2 NG3 3 4 3
63 IDC No 30 T2 N2 Pos 5 G3 NG3 2 4 2
55 IDC Yes 15 T1 N0 Neg 0 G3 NG3 2 2
59 IDC Yes 10 T1 N0 Neg 0 G3 NG3 2 3
44 IDC No 10 T1 N0 Neg 0 G1 NG2 0 0
59 IDC Yes 20 T1 N1 Pos 3 G2 NG2 0 2 2 2
39 IDC Yes 40 T2 N3 Pos 34 G2 NG3 2 4 4 3
71 IDC No 25 T2 N1 Pos 1 G1 NG2 0 1
73 ILC No 6 T1 N2 Pos 9 G2 NG3 0 0 0
73 IDC Yes 20 T1 N1 Pos 1 G2 NG3 0 1 2
85 IDC Yes 25 T2 N1 Pos 2 G3 NG3 1 3 3 2
79 IDC Yes 25 T4 N1 Pos 3 G2 NG2 1 2
78 IDC Yes 30 T2 N3 Pos 13 G3 NG3 2 4 4 4
55 IDC No 11 T1 N0 Neg 0 G1 NG2 1 2
82 IDC No 40 T2 N1 Pos 1 G2 NG3 0 0
61 IDC No 25 T2 N0 Neg 0 G2 NG3 0 0
66 IDC No 25 T2 N0 Neg 0 G3 NG3 1 2
76 IDC Yes 20 T1 N1 Pos 3 G3 NG3 1 3 4 3
71 IDC No 10 T1 N0 Neg 0 G1 NG1 0 1
76 ILC Yes 10 T1 G2 NG2 0 1 1
70 IDC Yes 37 T2 N0 Neg 0 G3 NG3 0 1 1
66 IDC No 40 T2 N0 Neg 0 G3 NG3 0 0
64 IDC Yes 12 T1 N0 Neg 0 G3 NG3 0 0
40 IDC No 15 T1 N1 Pos 3 G3 NG3 0 1 2 2
81 IDC Yes 25 T2 N3 Pos 30 G3 NG3 1 3 4 3
51 ILC No 13 T1 N0 Neg 0 G2 NG2 0 1
63 IDC No 30 T2 N0 Neg 0 G3 NG3 0 1
39 IDC Yes 20 T1 N2 Pos 4 G3 NG3 2 4 3 3
73 ILC No 24 T2 N0 Neg 0 G2 NG2 1 2
74 IDC No 20 T1 N0 Neg 0 G2 NG3 0 0
73 IDC No 10 T1 N0 Pos 0 G2 NG3 0 2 2
86 IDC Yes 15 T1 N0 Neg 0 G3 NG3 0 1 2
47 IDC No 25 T2 N1 Pos 1 G3 NG3 1 1 2
57 IDC Yes 20 T1 N1 Pos 2 G2 NG3 1 2 2 2
57 IDC Yes 70 T3 N3 Pos 15 G3 NG3 2 4 3 3
Age, primary tumor diameter, pTN, grade (G), nuclear grade (NG), and IL-6 scoring are also reported [mass, tumor front (Fr), lymphovascular tumor emboli (LVI), and lymph nodes (LN)]. Cyto-
plasmic IL-6 Score System: <1% = 0; 1% to 10% = 1; 10% to 25% = 2; 25% to 50% = 3; >50% = 4.
Figure W1. Comparison of 1833-pB and 1833–IL-6 cells/tumors. (A) In vitro growth. Equal numbers of 1833-pB and 1833–IL-6 cells were
grown, and cell viability was determined daily using calcein AM fluorescence. Values are expressed as the mean of triplicates. No differ-
ences in growth rates were observed. (B) Representative histologic images of 1833-pB and 1833–IL-6 MFP tumor sections stained for
pStat3, CD45, and Meca-32. (C) Representative IF images for CD11b+ and Gr1+ cells (red) found in 1833 and 1833–IL-6 (green tumor cells;
blue nuclei) MFP tumors. *P < .05.
Figure W2. Consequences of IL-6R blockade. (A) Extracts from 1833–IL-6 cells treated with control IgG (−) or IL-6RAb (+) were analyzed for
pStat3, Stat3, and tubulin levels by Western blot analysis. (B) Trans-signaling. Extracts from 67NR cells (murine mammary epithelial cells)
treated with ligands, conditioned media, and antibodies for 2 hours [control Ab (C), IL-6, sIL-6R, IL-6 + sIL-6R, IL-6 + sIL-6R + IL6RAb,
conditioned media from 1833–IL-6 cells (CM), and CM + IL-6Rab] were analyzed for pStat3 and actin by Western blot analysis. (C) Repre-
sentative histologic images of MFP tumors and (D) lung sections from 1833–IL-6–injected mice treated with control antibody (C) or IL-6R
antibody (IL-6RAb) stained for pStat3, CD45, and Meca-32. (E) Representative IF images of CD11b+ and Gr1+ cells (red) from mice bearing
1833–IL-6 MFP tumors (green) treated with isotype control and IL-6RAb.
Figure W3. Stat3 regulates tumor growth. (A) A schematic of the IL-6 promoter with a putative Stat3 binding site in yellow and a canonical
NF-κB binding site in blue. Primer binding sites are indicated at−322 and−3 from the ATG. 4175 cells were subjected to ChIP assay using
antibodies to Stat3 (S3) or IgG as a negative control. Co-precipitated DNA was amplified by PCR using primers flanking the Stat3 binding
sites at −322 and −3 of the IL-6 promoter. The input was 5% of the total. (B) Stat3-shRNA lentiviral construct (ShS3) and control vector
(CSh) were introduced into the 4175 cells. Human Stat3 was introduced into ShS3 cells (ShS3 + S3). Extracts were isolated from these
and analyzed for pStat3, Stat3, and tubulin. (C) 4175 Control, ShS3, and ShS3 + S3B cells (1 × 106) were injected into the MFP, and tumor
growth was determined weekly by normalized BLI (n= 6mice/group). (D) 4175 Control and ShS3 cells (1 × 105) were injected intravenously
leading to lung colonization, and metastatic growth was determined weekly by normalized BLI (n = 6 mice/group). (E) Representative
histologic images of 4175 and 4175ShS3 MFP tumor sections stained for H&E, Stat3, Ki67, Meca-32, CD45, and IL-6. *P < .05.
Figure W4. Tumor-extrinsic effects of Stat3 deficiency. (A) Extracts fromStat3−/− and Stat3+/+ PyMT tumor–derived cell lineswere analyzed
for pStat3 and tubulin. (B) Representative light microscopy images of mammospheres cultured from PyMT S3+ and PyMT S3− tumors.
(C) Representative images of PyMT S3+ and PyMT S3− MFP tumors. (D) The proportion (%) of CD3+, CD4+, and CD8+ cells in S3+ and
S3− tumors was determined by flow cytometry (n = 5). *P < .05.
